促红细胞生成素在心力衰竭合并贫血患者治疗管理中的作用

O. Centurión, J. Caceres
{"title":"促红细胞生成素在心力衰竭合并贫血患者治疗管理中的作用","authors":"O. Centurión, J. Caceres","doi":"10.15406/JCCR.2020.13.00479","DOIUrl":null,"url":null,"abstract":"The introduction of beta adrenergic blockers associated with angiotensin converting enzyme (ACE) inhibitors in the treatment of HF led to a significant improvement in prognosis.11–13 The benefit obtained with beta-adrenergic blockers encouraged the search for new drugs that not only more completely block the activation of the reninangiotensin and sympathetic systems, but also allow modulating other activated phenomena in heart failure, such as inflammation and endothelial dysfunction.14 However, in recent years we have found that multiple studies analyzing the benefit of new drugs obtained controversial results. From new ACE inhibitors, endothelin and tumor necrosis factor alpha inhibitors, and the same angiotensin receptor antagonists that have brought benefits, but far below the expectations created. This indicates that there is probably no additional benefit to be gained by trying to increase the blockage of circulating neurohormones; in fact, some authors have suggested that this pathway has been exhausted and other therapeutic options must be sought.15 Current guidelines on heart failure recommend the use Sacubitril/ Valsartan (S/V), an angiotensin receptorneprilysin inhibitor, in replacement of the renin–angiotensin–aldosterone system inhibition in ambulatory patients with HF and reduced ejection fraction still symptomatic despite optimal medical therapy.16 This recommendation comes from a single randomized study named PARADIGM-HF trial, which showed the superiority of Sacubitril-Valsartan compared to Enalapril in reducing the incidence of cardiovascular death or hospitalizations for HF.17 Nevertheless, despite the improvements in clinical management and medical therapy of HF, the outcome of these patients still remains poor.18 The persistence of significant ventricular remodeling despite optimized medical treatment has been associated with a poorer prognosis in heart failure. In this sense, possible interventions to cut the signals that activate the mechanisms that mediate progressive ventricular remodeling are being investigated in recent years. Despite the effort made, there is still a long way to go before it can become a reality that allows newer drugs to be generated.19 The lack of effective new treatments has led to a deeper analysis of the factors that affect the prognosis of heart failure, and anemia is one of them. Increasing attention is paid to anemia in patients with HF due to the relationship it has with its prognosis, which, despite all the treatments that have been used in HF, continues to be poor.5,6 This relationship had previously been observed by several authors, both in terms of mortality and the need for new hospital admissions for HF. Furthermore, this association has been observed in hospitalized and outpatients. In fact, anemia is usually frequent in patients with HF in advanced stages of the disease. There is no doubt that correcting anemia can improve symptoms by correcting the oxygen supply to the tissues. Treatment with recombinant erythropoietin (EPO) and parenteral iron improves the functional class, ventricular function, and quality of life of these patients and also reduces the need for diuretics, both oral and intravenous.7–10","PeriodicalId":15200,"journal":{"name":"Journal of Cardiology & Current Research","volume":"56 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2020-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Erythropoietin role in the therapeutic management of heart failure patients with anemia\",\"authors\":\"O. Centurión, J. Caceres\",\"doi\":\"10.15406/JCCR.2020.13.00479\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The introduction of beta adrenergic blockers associated with angiotensin converting enzyme (ACE) inhibitors in the treatment of HF led to a significant improvement in prognosis.11–13 The benefit obtained with beta-adrenergic blockers encouraged the search for new drugs that not only more completely block the activation of the reninangiotensin and sympathetic systems, but also allow modulating other activated phenomena in heart failure, such as inflammation and endothelial dysfunction.14 However, in recent years we have found that multiple studies analyzing the benefit of new drugs obtained controversial results. From new ACE inhibitors, endothelin and tumor necrosis factor alpha inhibitors, and the same angiotensin receptor antagonists that have brought benefits, but far below the expectations created. This indicates that there is probably no additional benefit to be gained by trying to increase the blockage of circulating neurohormones; in fact, some authors have suggested that this pathway has been exhausted and other therapeutic options must be sought.15 Current guidelines on heart failure recommend the use Sacubitril/ Valsartan (S/V), an angiotensin receptorneprilysin inhibitor, in replacement of the renin–angiotensin–aldosterone system inhibition in ambulatory patients with HF and reduced ejection fraction still symptomatic despite optimal medical therapy.16 This recommendation comes from a single randomized study named PARADIGM-HF trial, which showed the superiority of Sacubitril-Valsartan compared to Enalapril in reducing the incidence of cardiovascular death or hospitalizations for HF.17 Nevertheless, despite the improvements in clinical management and medical therapy of HF, the outcome of these patients still remains poor.18 The persistence of significant ventricular remodeling despite optimized medical treatment has been associated with a poorer prognosis in heart failure. In this sense, possible interventions to cut the signals that activate the mechanisms that mediate progressive ventricular remodeling are being investigated in recent years. Despite the effort made, there is still a long way to go before it can become a reality that allows newer drugs to be generated.19 The lack of effective new treatments has led to a deeper analysis of the factors that affect the prognosis of heart failure, and anemia is one of them. Increasing attention is paid to anemia in patients with HF due to the relationship it has with its prognosis, which, despite all the treatments that have been used in HF, continues to be poor.5,6 This relationship had previously been observed by several authors, both in terms of mortality and the need for new hospital admissions for HF. Furthermore, this association has been observed in hospitalized and outpatients. In fact, anemia is usually frequent in patients with HF in advanced stages of the disease. There is no doubt that correcting anemia can improve symptoms by correcting the oxygen supply to the tissues. Treatment with recombinant erythropoietin (EPO) and parenteral iron improves the functional class, ventricular function, and quality of life of these patients and also reduces the need for diuretics, both oral and intravenous.7–10\",\"PeriodicalId\":15200,\"journal\":{\"name\":\"Journal of Cardiology & Current Research\",\"volume\":\"56 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-06-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Cardiology & Current Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.15406/JCCR.2020.13.00479\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cardiology & Current Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15406/JCCR.2020.13.00479","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

引入β肾上腺素能阻滞剂联合血管紧张素转换酶(ACE)抑制剂治疗心衰可显著改善预后。-肾上腺素能阻滞剂的益处鼓励了对新药物的探索,这些新药物不仅能更彻底地阻断肾血管紧张素和交感神经系统的激活,而且还能调节心力衰竭中的其他激活现象,如炎症和内皮功能障碍然而,近年来我们发现,分析新药益处的多项研究得出了有争议的结果。从新的ACE抑制剂,内皮素和肿瘤坏死因子α抑制剂,同样的血管紧张素受体拮抗剂带来的好处,但远远低于预期创造。这表明,试图增加循环神经激素的阻塞可能没有额外的好处;事实上,一些作者认为这一途径已经用尽,必须寻求其他治疗方案目前的心力衰竭指南推荐使用舒比利/缬沙坦(S/V),一种血管紧张素受体抑制剂,用于替代肾素-血管紧张素-醛固酮系统抑制剂,用于心衰和射血分数降低的门诊患者,尽管最佳药物治疗仍有症状这一建议来自一项名为PARADIGM-HF试验的随机研究,该研究表明,与依那普利相比,沙比替-缬沙坦在降低HF心血管死亡或住院发生率方面具有优势。然而,尽管HF的临床管理和药物治疗有所改善,但这些患者的预后仍然很差尽管经过优化的药物治疗,但持续存在显著的心室重构与心力衰竭的预后较差有关。从这个意义上说,近年来正在研究切断激活介导进行性心室重构机制的信号的可能干预措施。尽管做出了努力,但要使新药的产生成为现实,还有很长的路要走缺乏有效的新治疗方法导致对影响心力衰竭预后的因素进行更深入的分析,贫血是其中之一。由于心衰患者的贫血与其预后的关系,人们越来越关注心衰患者的贫血,尽管心衰患者已经使用了各种治疗方法,但其预后仍然很差。5,6先前有几位作者观察到这种关系,无论是在死亡率方面还是在心力衰竭的新住院需求方面。此外,在住院和门诊患者中也观察到这种关联。事实上,贫血通常常见于心衰晚期患者。毫无疑问,纠正贫血可以通过纠正组织的氧气供应来改善症状。重组促红细胞生成素(EPO)和肠外铁治疗可改善这些患者的功能等级、心室功能和生活质量,并减少口服和静脉注射利尿剂的需求7 - 10
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Erythropoietin role in the therapeutic management of heart failure patients with anemia
The introduction of beta adrenergic blockers associated with angiotensin converting enzyme (ACE) inhibitors in the treatment of HF led to a significant improvement in prognosis.11–13 The benefit obtained with beta-adrenergic blockers encouraged the search for new drugs that not only more completely block the activation of the reninangiotensin and sympathetic systems, but also allow modulating other activated phenomena in heart failure, such as inflammation and endothelial dysfunction.14 However, in recent years we have found that multiple studies analyzing the benefit of new drugs obtained controversial results. From new ACE inhibitors, endothelin and tumor necrosis factor alpha inhibitors, and the same angiotensin receptor antagonists that have brought benefits, but far below the expectations created. This indicates that there is probably no additional benefit to be gained by trying to increase the blockage of circulating neurohormones; in fact, some authors have suggested that this pathway has been exhausted and other therapeutic options must be sought.15 Current guidelines on heart failure recommend the use Sacubitril/ Valsartan (S/V), an angiotensin receptorneprilysin inhibitor, in replacement of the renin–angiotensin–aldosterone system inhibition in ambulatory patients with HF and reduced ejection fraction still symptomatic despite optimal medical therapy.16 This recommendation comes from a single randomized study named PARADIGM-HF trial, which showed the superiority of Sacubitril-Valsartan compared to Enalapril in reducing the incidence of cardiovascular death or hospitalizations for HF.17 Nevertheless, despite the improvements in clinical management and medical therapy of HF, the outcome of these patients still remains poor.18 The persistence of significant ventricular remodeling despite optimized medical treatment has been associated with a poorer prognosis in heart failure. In this sense, possible interventions to cut the signals that activate the mechanisms that mediate progressive ventricular remodeling are being investigated in recent years. Despite the effort made, there is still a long way to go before it can become a reality that allows newer drugs to be generated.19 The lack of effective new treatments has led to a deeper analysis of the factors that affect the prognosis of heart failure, and anemia is one of them. Increasing attention is paid to anemia in patients with HF due to the relationship it has with its prognosis, which, despite all the treatments that have been used in HF, continues to be poor.5,6 This relationship had previously been observed by several authors, both in terms of mortality and the need for new hospital admissions for HF. Furthermore, this association has been observed in hospitalized and outpatients. In fact, anemia is usually frequent in patients with HF in advanced stages of the disease. There is no doubt that correcting anemia can improve symptoms by correcting the oxygen supply to the tissues. Treatment with recombinant erythropoietin (EPO) and parenteral iron improves the functional class, ventricular function, and quality of life of these patients and also reduces the need for diuretics, both oral and intravenous.7–10
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信